Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial
December 20, 2022 08:00 ET
|
Immix Biopharma, Inc.
16th patient dosed with IMX-110 to dateThis is the second patient dosed with IMX-110 in December 2022Patients undergo CT scans every 8 weeks after dosing to assess tumor response to IMX-110; clinical...